Company

Bolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area.

Bolt’s highly qualified management team includes experienced leaders in immuno-oncology drug discovery, development and commercialization. Our goal is to leverage our myeloid biology expertise to discover, develop and commercialize transformative treatments to address key unmet medical needs for patients with cancer.

Management Team

Randall Schatzman, Ph.D.

Chief Executive Officer

Randall Schatzman, Ph.D., Chief Executive Officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr.

Randall Schatzman, Ph.D.

Chief Executive Officer

Randall Schatzman, Ph.D., Chief Executive Officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.

David Dornan, Ph.D.

Chief Scientific Officer

David Dornan, Ph.D., Chief Scientific Officer, joined Bolt Biotherapeutics in 2017. He is working to harness the exciting technologies at Bolt to discover and develop the

David Dornan, Ph.D.

Chief Scientific Officer

David Dornan, Ph.D., Chief Scientific Officer, joined Bolt Biotherapeutics in 2017. He is working to harness the exciting technologies at Bolt to discover and develop therapeutics that may exploit myeloid cell biology to generate a robust anti-tumor immune response. Prior to Bolt, Dr. Dornan led Oncology Research at Gilead and was working to build a group dedicated to identifying and developing anti-cancer therapeutics that could have utility in PD1-refractory patients that encompassed immuno-oncology and cancer driver targeted therapies. Before that, he spent 10 years at Genentech serving in roles of increasing responsibility and played key roles in target discovery and validation, as well as translational research programs to determine the optimum patient population that would benefit from Genentech’s anti-cancer therapeutics across large and small molecule programs. He began his tenure at Genentech as a post-doctoral fellow where he pursued his interest in identifying potential novel druggable targets in the laboratory of Dr. Vishva Dixit. Dr. Dornan received his Ph.D. from the University of Dundee in the United Kingdom for studies on cancer-dependent gene transcription.

Edith A. Perez, M.D.

Chief Medical Officer

Edith A. Perez, M.D., Chief Medical Officer, joined Bolt Biotherapeutics in 2020 and is an internationally recognized translational researcher and cancer specialist known

Edith A. Perez, M.D.

Chief Medical Officer

Edith A. Perez, M.D., Chief Medical Officer, joined Bolt Biotherapeutics in 2020 and is an internationally recognized translational researcher and cancer specialist known for her strategic vision in designing innovative clinical trials and passion of the patient. She is Professor of Medicine at Mayo Clinic and Director of the Mayo Clinic Breast Cancer Translational Genomics Program, where she has practiced for two decades. Prior to joining Bolt, Dr. Perez was the vice president and head of the BioOncology-U.S. medical affairs unit at Genentech for three years. She earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. In addition, she completed her fellowship training at the University of California, Davis. Dr. Perez is board certified in internal medicine, medical oncology and hematology.

William Quinn

Chief Financial Officer

Willie Quinn, Chief Financial Officer, joined Bolt Biotherapeutics in 2020. Prior to joining Bolt, Willie served as the chief financial officer and senior vice president

William Quinn

Chief Financial Officer

Willie Quinn, Chief Financial Officer, joined Bolt Biotherapeutics in 2020. Prior to joining Bolt, Willie served as the chief financial officer and senior vice president corporate development of Sunesis Pharmaceuticals (SNSS). He led Sunesis’ fundraising and partnering efforts, raising over $60 million in public funding and signing multiple deals with industry partners. Prior to Sunesis he led Bullet Biotechnology, a company that he co-founded to develop cancer immunotherapies based on technology from Stanford University, as chief executive officer. Willie was instrumental in establishing the infrastructure at Jazz Pharmaceuticals (JAZZ), where he was one of the first employees and worked for more than eight years. He rose to head of corporate development, also overseeing strategy and investor relations, helping Jazz transform from a private startup to a public, profitable specialty pharmaceutical company. Before Jazz, Willie was the chief financial officer and chief operating officer of Novation Biosciences, a biotechnology software company that was acquired by Agilent Technologies. He currently serves on the board of A Foundation Building Strength, a nonprofit with a mission to find treatments for Nemaline Myopathy. Willie earned an M.A. and B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Grant Yonehiro

Chief Business Officer

Grant Yonehiro joined Bolt Biotherapeutics as the company’s Chief Business Officer in 2016. Grant has been responsible for business and corporate development, strategy,

Grant Yonehiro

Chief Business Officer

Grant Yonehiro joined Bolt Biotherapeutics as the company’s Chief Business Officer in 2016. Grant has been responsible for business and corporate development, strategy, commercialization and general management within biotechnology companies for over 25 years with significant transactional and operational responsibilities. He served as president and chief executive officer of Perseid Therapeutics from inception through acquisition by Astellas Pharma and stayed on post-acquisition as president of an Astellas operating site. He served as chief business officer for Berkeley Lights and Maxygen and also held various senior management positions at GenVec including vice president of commercial operations, vice president of product management and vice president of drug development. Prior to GenVec, he served in business development at Cell Genesys, in investment banking at Piper Jaffray and in the Technology Transfer Office at Lawrence Berkeley National Laboratory. Grant graduated Magna Cum Laude from the University of Minnesota with a Bachelor of Individualized Studies and received his M.B.A. from the Haas School of Business at UC Berkeley.

Michael N. Alonso, Ph.D.

Vice President, Immunology & Pharmacology

Michael Alonso, Ph.D., Vice President, Immunology & Pharmacology, is a scientific co-founder at Bolt Biotherapeutics and co-invented Bolt’s promising technology. Mi

Michael N. Alonso, Ph.D.

Vice President, Immunology & Pharmacology

Michael Alonso, Ph.D., Vice President, Immunology & Pharmacology, is a scientific co-founder at Bolt Biotherapeutics and co-invented Bolt’s promising technology. Michael is passionate about translating scientific discoveries into therapies that ensure cancer patients become cancer survivors. Dr. Alonso has deep expertise with myeloid biology and has over 10 years of experience in immunology, neuroscience and transplant biology. Prior to joining Bolt, Michael served as the lead scientist at a Bay Area biotechnology start-up and has held leadership roles at Stanford University. Michael is a well-published scientist who earned his Ph.D. from Stanford University School of Medicine and his Certificate in Entrepreneurship from Stanford’s Graduate School of Business. Michael graduated with distinction from the University of Illinois at Urbana-Champaign where he obtained his bachelors of science in molecular and cellular biology.

Wesley Burwell

Vice President, Head of Human Resources

Wesley Burwell joined Bolt Biotherapeutics in 2021 bringing more than 20 years of experience building and driving HR strategy for clinical-stage life science companies. Prior to Bolt, Wes was a senior

Wesley Burwell

Vice President, Head of Human Resources

Wesley Burwell joined Bolt Biotherapeutics in 2021 bringing more than 20 years of experience building and driving HR strategy for clinical-stage life science companies. Prior to Bolt, Wes was a senior HR leader at Global Blood Therapeutics where he supported the company’s exponential growth from early development through commercialization, led talent acquisition and established programs to foster learning and development and employee engagement.

Over the course of his career, Wes has held leadership roles in both life-science and technology companies, was founder of a successful recruiting and HR consulting practice and served on the boards of directors of several non-profits focused on healthcare and education. He is especially passionate about building mission-driven organizations with strong cultures and diverse, inclusive workforces.

Wes earned his M.B.A. in international business from the University of San Francisco and obtained a bachelor’s degree in human resource management from Golden Gate University.

Liang Fang, Ph.D.

Vice President, Biometrics & Bioinformatics

Liang Fang, Ph.D., Vice President, Biometrics & Bioinformatics, joined Bolt Biotherapeutics in 2021, bringing 15 years of experience in drug development, statistical

Liang Fang, Ph.D.

Vice President, Biometrics & Bioinformatics

Liang Fang, Ph.D., Vice President, Biometrics & Bioinformatics, joined Bolt Biotherapeutics in 2021, bringing 15 years of experience in drug development, statistical methods and applications in multiple areas such as oncology, cardiovascular, translational research, clinical pharmacology, and data sciences. Prior to joining Bolt, Liang was the Head of Biostatistics and Statistical Programming at MyoKardia, Inc. (2018-2020). He worked at Gilead Sciences (2013-2018) to build a group of statisticians and data scientists dedicated to biomarker research and clinical pharmacology programs. At Genentech (2008-2013) and Amgen (2005-2008), Liang worked in roles of increasing responsibility in the development of multiple therapeutics, including Prolia, Avastin, and Kadcyla. He is an internationally recognized leader in clinical research with over 30 peer-reviewed publications, one book, and numerous conference publications. Liang obtained his PhD from Kansas State University.

Bruce Hug, M.D., Ph.D.

Vice President, Early Development & Research Collaborations

Bruce Hug, M.D., Ph.D., Vice President, Early Development & Research Collaborations, joined Bolt Biotherapeutics in 2021 with 16 years of hematology and oncology drug development experience focuse

Bruce Hug, M.D., Ph.D.

Vice President, Early Development & Research Collaborations

Bruce Hug, M.D., Ph.D., Vice President, Early Development & Research Collaborations, joined Bolt Biotherapeutics in 2021 with 16 years of hematology and oncology drug development experience focused on early development. Prior to joining Bolt, Bruce worked in positions of increasing responsibility at several companies, most recently at GlaxoSmithKline, evaluating novel, early-phase immunotherapies. His academic experience includes Clinical Pathology residency and fellowship training, and later, clinical practice at the University of Pennsylvania. Bruce obtained his M.D. and Ph.D. degrees from Washington University where he studied gene regulation.

Amreen Husain, M.D.

Vice President, Clinical Development & Translational Medicine

Amreen Husain, M.D., Vice President, Clinical Development & Translational Medicine, joined Bolt Biotherapeutics in 2020 bringing 10 years of experience in oncology dr

Amreen Husain, M.D.

Vice President, Clinical Development & Translational Medicine

Amreen Husain, M.D., Vice President, Clinical Development & Translational Medicine, joined Bolt Biotherapeutics in 2020 bringing 10 years of experience in oncology drug development with a focus on breast and gynecologic cancers, immuno-oncology, and drug safety. Prior to joining Bolt, Amreen was at Roche/Genentech in roles of increasing responsibility in late-stage Oncology Development leading cross-functional teams in the development of Atezolizumab and Bevacizumab. She is an internationally recognized leader in clinical research with over 50 peer-reviewed publications and has served on cooperative groups and international professional societies. She previously practiced at Stanford University Medical Center as Associate Professor of Gynecologic Oncology and is board-certified in Obstetrics and Gynecology and Gynecologic Oncology. Amreen obtained her MD from New York Medical College, completed her Ob/Gyn residency at Cornell University Medical Center, and her gynecologic oncology fellowship at Memorial-Sloan Kettering Cancer Center.

Nathan Ihle, Ph.D.

Vice President, CMC & Quality

Nathan Ihle, Ph.D., Vice President, CMC & Quality, joined Bolt Biotherapeutics in 2019. Prior to joining Bolt, he was the founder and Principal at Ihle CMC Solutions.

Nathan Ihle, Ph.D.

Vice President, CMC & Quality

Nathan Ihle, Ph.D., Vice President, CMC & Quality, joined Bolt Biotherapeutics in 2019. Prior to joining Bolt, he was the founder and Principal at Ihle CMC Solutions. He has also served as the vice president of manufacturing strategy at Immunomedics, where he developed and implemented the supply strategy and supported the global commercialization of the company’s first antibody-drug conjugate product. He was also a key contributor to the company’s regulatory submissions. Before working at Immunomedics, Dr. Ihle worked for 16 years at Seattle Genetics as the vice president of CMC strategy and management. At Seattle Genetics, Dr. Ihle was responsible for CMC aspects of development and regulatory strategies for all corporate programs, portfolio and project management and alliance management. Dr. Ihle completed his post-doctoral work as an American Cancer Society Postdoctoral fellow at University of California, Berkeley after receiving his doctorate in Organic Chemistry from Stanford University.

Marcin Kowanetz, Ph.D.

Vice President, Target Validation & Translational Sciences

Marcin Kowanetz, Ph.D., Vice President, Target Validation & Translational Sciences, joined Bolt Biotherapeutics in 2018. He brings 13 years of pharmaceutical experien

Marcin Kowanetz, Ph.D.

Vice President, Target Validation & Translational Sciences

Marcin Kowanetz, Ph.D., Vice President, Target Validation & Translational Sciences, joined Bolt Biotherapeutics in 2018. He brings 13 years of pharmaceutical experience in drug discovery and development, with focus on cancer immunotherapy for molecules in early and late clinical stage. Prior to Bolt, Dr Kowanetz served at Genentech in roles of increasing responsibility in Oncology Biomarker Development, including biomarker lead for atezolizumab (anti-PD-L1) and overseeing cross functional teams identifying, developing, and implementing biomarker strategies for therapies at various stages of clinical development. Prior to that, he was in Research Drug Discovery where he focused on the identification and characterization of novel targets for the treatment of cancer. He is passionate about understanding mechanisms of response and resistance to cancer immunotherapy and developing personalized immunotherapies. Dr. Kowanetz has over 35 published papers, is named on several patents and has contributed chapters to multiple medical research textbooks. He holds a Ph.D. from the Ludwig Institute for Cancer Research at Uppsala University in Sweden and a Master of Science degree from the Institute of Molecular Biology at Jagiellonian University in Krakow, Poland.

Triona O’Hanlon

Vice President, Project Management

Triona O'Hanlon, Vice President, Project Management, joined Bolt Biotherapeutics in 2020. She has over 20 years of drug development experience spanning biologics, small m

Triona O’Hanlon

Vice President, Project Management

Triona O'Hanlon, Vice President, Project Management, joined Bolt Biotherapeutics in 2020. She has over 20 years of drug development experience spanning biologics, small molecules and cellular therapeutics in oncology, inflammation and neurology. Prior to joining Bolt, Triona was at Gilead Sciences for seven years, where she led the program management group for Hematology/Oncology division and Kite, Gilead's cell therapy division.

Prior to joining Gilead, Triona held program and alliance management roles at Ambit Biosciences, overseeing early development of Quizartinib, a FLT3 inhibitor, as well as Elan Pharmaceuticals, where she supported the clinical development and launch of Tysabri in collaboration with Biogen and lead the early development of an oral anti α4β7 integrin in rheumatoid arthritis.

Triona holds a BSc in Biochemistry and Biochemical Engineering from Dublin City University.

Brian Safina, Ph.D.

Vice President, Medicinal Chemistry & Bioconjugation

Brian Safina, Ph.D., serves as Vice President, Medicinal Chemistry & Bioconjugation for Bolt Biotherapeutics. He joined Bolt in 2018 with over 14 years of experience

Brian Safina, Ph.D.

Vice President, Medicinal Chemistry & Bioconjugation

Brian Safina, Ph.D., serves as Vice President, Medicinal Chemistry & Bioconjugation for Bolt Biotherapeutics. He joined Bolt in 2018 with over 14 years of experience in large pharma and has made contributions in multiple therapeutic areas including oncology, immunology and neuroscience. Prior to Bolt, Dr. Safina was at Genentech where he served in roles of increasing responsibility in Discovery Chemistry, which included serving as a project team leader for early and late stage projects with 30+ team members. He has published over 25 papers, and is named on over 25 granted patents and more than 10 patent applications. Dr. Safina holds a Ph.D. in organic chemistry from the University of California, San Diego.

Board of Directors

Edgar G. Engleman, M.D.

Founder and Director

Dr. Ed Engleman is professor of pathology and medicine at Stanford University Sc

Edgar G. Engleman, M.D.

Founder and Director

Dr. Ed Engleman is professor of pathology and medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. He is also co-director of the Immunology and Immunotherapy Program of the Stanford Cancer Institute. Dr. Engleman has authored more than 300 publications in medical and scientific journals and has trained more than 100 graduate students and postdoctoral scholars, many of whom have gone on to successful careers in industry and academia. Dr. Engleman is a co-founder and managing partner of Vivo Capital, a leading healthcare focused investment firm with offices in the U.S. and Asia. He has also co-founded a number of biopharmaceutical companies including Genelabs, Dendreon, Medeor and Tranquis. He is the lead inventor of the technology underlying Sipuleucel-T (Provenge), which was shown to extend life for patients with metastatic prostate cancer and was the first active immunotherapeutic agent to be approved by the FDA. Recently, Dr. Engleman’s laboratory discovered a promising new immunotherapy that activates dendritic cells in tumors in situ without requiring their removal and activation in vitro. This treatment was shown to eradicate a wide range of tumors in mouse models and provided the basis for the creation of Bolt Biotherapeutics. Dr. Engleman currently serves on the boards of several private biotechnology companies including Bolt. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.

Jim Healy, M.D., Ph.D.

Lead Independent Director

Jim Healy, M.D. Ph.D., is a General Partner of Sofinnova Investments with over 2

Jim Healy, M.D., Ph.D.

Lead Independent Director

Jim Healy, M.D. Ph.D., is a General Partner of Sofinnova Investments with over 20 years of experience funding innovative therapies. He is currently on the board of directors for Ascendis (ASND), Bolt (BOLT), Coherus (CHRS), Karuna (KRTX), Natera (NTRA), Nucana (NCNA), Y-mAbs (YMAB), and a board observer at Visen. Prior to Sofinnova, Dr. Healy held positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals, and ISTA Pharmaceuticals, Inc. Additionally, Dr. Healy has extensive board experience, serving on both private and public company boards, including Amarin Corporation, Auris Medical Holding AG, Edge Therapeutics, and Hyperion Therapeutics, as Chairman of the Board. In 2011, Dr. Healy won the IBF Risk Innovator Award and was named as one of the industry’s top leading Life Science investors in 2013 by Forbes Magazine. Dr. Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley.

Ashish Khanna, Ph.D.

Director

Dr. Ash Khanna is a Venture Partner at Pivotal bioVenture Partners and brings si

Ashish Khanna, Ph.D.

Director

Dr. Ash Khanna is a Venture Partner at Pivotal bioVenture Partners and brings significant experience in the venture capital, pharmaceutical and biotech arena. Most recently, he co-founded SutroVax, a Pivotal bioVenture Partners portfolio company, where he served as chief business officer. Previously he was president and chief business officer of Imagen Biotech, a VC-backed startup developing treatments for severe ophthalmic diseases. Prior to his operating roles, Dr. Khanna was a principal at SV Life Sciences (SVLS), a healthcare focused venture capital firm, where he led and managed investments in many biotech and diagnostic companies including, among others, Ophthotech, Sutro BioPharma, Mpex Pharmaceuticals, Good Start Genetics and Itero Biopharma. He started his career in the pharmaceutical industry at Bristol-Myers Squibb where he held various positions including Team Leader responsible for the clinical advancement of multiple diabetes programs including the currently marketed products, Onglyza® (Dipeptidyl peptidase-4 inhibitor) and Farxiga® (SGLT2 inhibitor). Dr. Khanna is a co-inventor on the Onglyza® patent. Dr. Khanna holds a Ph.D. in Pharmaceutics from the State University of New York, an M.B.A. in Finance from The Wharton School, and a B.S. in Pharmacy from the University of Bombay.

Kathleen LaPorte

Director

Kathy LaPorte has more than 30 years of experience building and operating private and public biotech companies

Kathleen LaPorte

Director

Kathy LaPorte has more than 30 years of experience building and operating private and public biotech companies. She currently serves as a director of Elysium Therapeutics, Precipio Diagnostics and D2G Oncology. Kathy was chief executive officer of Nodality Inc. as well as a founding partner of New Leaf Ventures, which was a spinout from the Sprout Group. Prior to that, Kathy served as a general partner of The Sprout Group for over 12 years.   She is passionate about helping founders, CEOs and organizations grow successfully and playing a meaningful role on outstanding boards. Kathy’s board experience is extensive and includes both private and public companies, as well as public-sector boards such as the California Institute of Regenerative Medicine (CIRM).  She has served on more than a dozen public company boards, including companies such as Affymax, ISTA Pharmaceuticals, and Onyx Pharmaceuticals.  Kathy has served on 12 audit committees, and chaired several. She is a Qualified Financial Expert. Kathy has a B.S. degree in Biology from Yale University and an M.B.A. from the Stanford University Graduate School of Business.

Frank D. Lee

Director

With over 25 years’ global experience in product development and commercial leadership across a wide range o

Frank D. Lee

Director

With over 25 years’ global experience in product development and commercial leadership across a wide range of therapeutic areas within the biotech and pharmaceutical industry, Frank joined as chief executive officer of Forma Therapeutics in March 2019. Most recently serving as senior vice president, global product strategy and therapeutic area head for the immunology, ophthalmology and infectious diseases at Genentech, a member of the Roche Group, he was responsible for driving development and commercial strategy for a broad portfolio of molecules in development and for global in-line product sales of more than $11 billion. Frank’s 13-year career path at Genentech included leadership positions of increasing scope and responsibility for delivering transformative medicines to patients. Previously, as vice president of the HER2/Breast Cancer Franchise, Frank was responsible for the U.S. P&L for Herceptin®, Perjeta® and Kadcyla®, driving revenues over $4 billion and launching the first HER2 neoadjuvant indication shaping a new market and treatment paradigm for early HER2 breast cancer patients. As vice president of oral oncolytics, Frank held P&L responsibility for Tarceva®, Zelboraf®, Erivedge® and Xeloda®, advancing personalized medicine for cancer patients with EGFR+ NSCLC and BRAF+ melanoma and establishing a new treatment option for patients with advanced basal cell carcinoma. Prior to joining Genentech, Frank spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development. Frank received a bachelor’s degree in chemical engineering from Vanderbilt University and an MBA in marketing and finance from the Wharton Graduate School of Business. He previously served on the board of directors of the Genentech Foundation.

Richard A. Miller, M.D.

Director

Dr. Richard Miller currently serves as co-founder, president and chief executive

Richard A. Miller, M.D.

Director

Dr. Richard Miller currently serves as co-founder, president and chief executive officer of Corvus Pharmaceuticals, a public biotechnology company. He co-founded and was chief executive officer of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, vice president and director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude and completed residency and fellowship programs in internal medicine and medical oncology at Stanford University Medical Center. He is a board-certified oncologist and is currently adjunct clinical professor of medicine (oncology) at Stanford University Medical Center.

Brian O'Callaghan

Director

Brian O’Callaghan is a Life Science Executive with extensive experience within the biotech, big pharma and C

Brian O'Callaghan

Director

Brian O’Callaghan is a Life Science Executive with extensive experience within the biotech, big pharma and CRO sectors. He also has extensive global experience, having lived and worked in 5 different countries, as well as both sides of the US. He joined ObsEva in November 2020, as Chief Executive Officer to lead the Company through its future development, regulatory filings and product launches.

Prior to joining ObsEva, Brian has held CEO positions at Petra Pharma, Acucela, Sangart and BioPartners, as well as having held senior management positions at Pfizer, Merck Serono, Novartis, Covance and NPS Pharmaceuticals.

Brian has experience running both public and private companies, M&A’s, IPO’s, fundraising, divestments, spin-outs and strategic alliances. His operational experience is also wide ranging, having managed multiple businesses and programs, across many therapeutic areas, from concept through to commercialization. He also has extensive Board experience, having served on numerous biotech and 501c3 Boards.

Randall Schatzman, Ph.D.

CEO and Board Member

Dr. Randall Schatzman, Chief Executive Officer and board member, joined Bolt Bio

Randall Schatzman, Ph.D.

CEO and Board Member

Dr. Randall Schatzman, Chief Executive Officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.

Mahendra G. Shah, Ph.D.

Director

Dr. Mahendra G. Shah is a pharmaceutical entrepreneur and executive who has been

Mahendra G. Shah, Ph.D.

Director

Dr. Mahendra G. Shah is a pharmaceutical entrepreneur and executive who has been at healthcare investment firm, Vivo Capital, since March 2010. He is also the founder and executive chairman of Semnur Pharmaceuticals. Dr. Shah currently serves on the boards of Homology Medicines Inc. (NASDAQ: FIXX) and Soleno Therapeutics Inc (NASDAQ: SLNO), and is a member of the board of trustees of St. John’s University. Dr. Shah is also a board member and charter member of EPPIC and a charter member of TIE.

From 2005 to 2009, he was the founder, chairman and chief executive officer of NextWave Pharmaceuticals, a pediatric focused specialty pharmaceutical company, which was sold to Pfizer for a total of $700 million in upfront and milestone payments. From 1993 to 2003 he was the chairman and chief executive officer of First Horizon Pharmaceuticals, a publicly traded specialty pharmaceutical company, where he raised over $200 million and built a highly profitable company before it was sold to Shionogi Pharmaceuticals for $1.4 billion. Prior to that, he held positions with E. J. Financial Enterprises, which manages a fund that invests in healthcare companies and with Fujisawa USA (Astellas), and before that, he worked in various scientific and management positions with Schering-Plough and Bristol Myers-Squibb. He previously served on the boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics (INGN), Inpharmakon, Protomed, Structural Bioinformatics, and Zarix. Dr. Shah received his Ph.D. in industrial pharmacy from St. John’s University and his Bachelors and Masters Degrees in Pharmacy from L.M. College of Pharmacy in Gujarat, India.

Scientific Advisory Board

Lawrence Fong, M.D.

Cancer Immunotherapy Program Leader

Lawrence Fong, M.D., is an Efim Guzik distinguished professor in the Division of Hematology/Oncology at the Un

Lawrence Fong, M.D.

Cancer Immunotherapy Program Leader

Lawrence Fong, M.D., is an Efim Guzik distinguished professor in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF). Dr. Fong is focused on developing immunotherapies for different cancers including prostate, kidney, bladder, melanoma, and GI cancers. As a physician-scientist, Dr. Fong also leads a translational immunotherapy laboratory. He has been involved in both pre-clinical and clinical studies for many cutting-edge immunotherapies. Dr. Fong obtained his M.D. at Stanford University, completed internal medicine training at the University of Washington, and an oncology fellowship at Stanford University with Drs. Ed Engleman and Mark Davis focused on tumor immunology. He served on the program committees and editorial boards for ASCO and AACR. He is co-director of the Parker Institute for Cancer Immunotherapy at UCSF and is the site primary investigator for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN).

Priti Hegde, Ph.D.

Chief Scientific Officer

As chief scientific officer at Foundation Medicine, Priti Hegde, Ph.D., oversees clinical product development,

Priti Hegde, Ph.D.

Chief Scientific Officer

As chief scientific officer at Foundation Medicine, Priti Hegde, Ph.D., oversees clinical product development, cancer genomics and early-stage research, as well as regulatory strategies for the company’s comprehensive genomic profiling portfolio. Prior to joining Foundation Medicine, Dr. Hegde spent 12 years at Genentech, a member of Roche Group, most recently serving as senior director and principal scientist in oncology biomarker development, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy. Dr. Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union as well as its forthcoming diagnostic filings. Prior to Genentech, she worked at GlaxoSmithKline. Dr. Hegde completed her post-doctoral fellow at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy from Mumbai University, India.

Roy S. Herbst, M.D., Ph.D.

Chief of Medical Oncology, Director for Translational Research

Roy S. Herbst, M.D., Ph.D., is ensign professor of medicine, professor of pharmacology, chief of medical oncol

Roy S. Herbst, M.D., Ph.D.

Chief of Medical Oncology, Director for Translational Research

Roy S. Herbst, M.D., Ph.D., is ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research at Yale Cancer Center (YCC) and Yale School of Medicine. Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy, serving as principal investigator for numerous clinical trials for advanced stage lung cancers. This work led to the approval of several therapies (such as Gefitinib, Cetuximab, Bevacizumab, Axitinib, Atezolizumab, and Pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His work on "umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. He works closely with public-private partnerships to develop large clinical studies, such as Lung-MAP. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology (ASCO). Dr. Herbst’s work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

Nils Lonberg, Ph.D.

Executive in Residence

Nils Lonberg is currently an Executive in Residence at Canaan Partners. Dr. Lonberg led drug discovery and pla

Nils Lonberg, Ph.D.

Executive in Residence

Nils Lonberg is currently an Executive in Residence at Canaan Partners. Dr. Lonberg led drug discovery and platform development teams in the biotech and pharma industry for the last 30 years, most recently as Senior Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb. Prior to that he was Scientific Director at Genpharm International and Medarex, where his research groups developed genetically engineered strains of mice with human immunoglobulin genes that have been used to discover 10 FDA-approved antibody therapeutics, including ipilimumab and nivolumab, two drugs discovered by Dr. Lonberg’s team that target immune-attenuating pathways to activate patient immune responses to multiple cancers (so-called "checkpoint blockade" therapies). Dr. Lonberg received his PhD in Biochemistry and Molecular Biology from Harvard University (Cambridge, MA) in 1985, and was elected to the National Academy of Engineering in 2015.

Bruce D. Roth, Ph.D.

Principal

Bruce D. Roth, Ph.D. is best known as the inventor of Lipitor®, for which he has received numerous awards, in

Bruce D. Roth, Ph.D.

Principal

Bruce D. Roth, Ph.D. is best known as the inventor of Lipitor®, for which he has received numerous awards, including the 2013 Perkin Medal, the highest award given to industrial chemists in the United States. Dr. Roth is now active as a biopharmaceutical research consultant. Prior to founding his consulting practice, between the years of 2007 and 2017, he held positions of increasing responsibility at Genentech, the last one being senior vice president of gRED (Genentech Research and Early Development) small molecule drug discovery and co-leader of gRED research. Before that, he served as vice president of chemistry at Pfizer Global Research and Development, Ann Arbor Laboratories, and prior to that, was an adjunct associate professor in the Department of Medicinal Chemistry in the School of Pharmacy of the University of Michigan.